BMY•benzinga•
Bristol-Myers Faces Renewed $6.7 Billion Lawsuit Over Drug Approval Delays Amid Resolved Trustee Issue
Summary
Bristol-Myers faces a renewed $6.7 billion lawsuit, alleging delayed approval for drugs like Breyanzi, affecting contingent value rights holders' payments.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 15, 2024 by benzinga